bone marrow on day +1 while patients received PBPC over 3 days in one of two schedules: either on days (+1, +2 and +3), or days (Ϫ1, 0 and +1). Patients who received PBPC Peripheral blood progenitor cells (PBPC) are increasingly used as the source of stem cells in both the autoon days Ϫ1, 0, and +1 had fewer days of neutropenia. None of the patients in this study received PBPC infusion over logous and allogeneic settings. Based on previous early non-randomized studies reporting enhanced 1 day as a comparison group. The practice of infusing PBPCs over several days is not engraftment following fractionated autologous PBPC infusion, some centers and study groups infuse PBPC uncommon. Several intergroup breast cancer trials in the United States either require, or recommend, the infusion of over 3 days. To study the possible benefit of multiple day PBPC infusion, 60 patients receiving high-dose PBPCs over several days. The Cancer and Leukemia Group B study 9082, a randomized study of ABMT vs standardchemotherapy and autologous progenitor cell transplantation (ABMT) were randomized to receive their PBPC dose chemotherapy for women with stage II or stage III breast cancer with greater than 10 axillary nodes, requires divided over 1, 2 or 3 days. Stem cells were mobilized with G-CSF 5 g/kg for 7 days and PBPC were colthat PBPC be administered on day Ϫ1, day 0 and day +1.
/l was 11 days for the group receiving their cells
nodes (SWOG 9623) , allows the infusion of PBPCs over several consecutive days. as a single infusion and 12 days in the other two groups. We conclude that expanding PBPC infusion over 2 or
We have extensive experience infusing PBPC over 1 day and hypothesized that a single day infusion is well tolerated 3 days does not enhance engraftment or reduce toxicity. Keywords: stem cells; PBPC; engraftment; bone marand results in similar engraftment compared to published results with multiple day infusions. To test this hypothesis row transplantation we designed a prospective randomized study comparing a single day PBPC infusion to two multiple day schedules.
High-dose chemotherapy and autologous bone marrow/hematopoietic cell transplantation (ABMT) is Patients and methods widely and increasingly used in the treatment of various malignancies including non-Hodgkin's lymphoma, HodgSixty consecutive patients undergoing ABMT from August kin's disease and breast cancer. The major morbidity of l995 to May l996 were prospectively randomized into three autologous transplantation remains the potential for bleedgroups; the first group received all PBPC in a single ing and infections related to the 10-12 day period of pancyinfusion while the other two groups received their PBPC topenia. The infusion of progenitor cells themselves may divided into two or three portions given over 2 or 3 days, be complicated by chills, flushing, wheezing and fluid overrespectively. Patient characteristics are shown in Table 1 . load. In an effort to decrease the toxicity associated with Eligibility criteria included normal pulmonary function progenitor cell infusion, and to potentially enhance (DLCO Ͼ50% predicted); normal cardiac function (left engraftment, Peters et al 1 reported a preliminary study of ventricular ejection fraction Ͼ50%); adequate hepatic func-48 patients treated with high-dose chemotherapy followed tion (serum transaminases levels less than twice the upper by bone marrow and PBPC infusion. All patients received limit of normal); and adequate renal function (serum creatinine Ͻ2 mg/dl). Granulocyte recovery was defined as the number of days from the first day of re-infusion of PBPC prophylactic antibiotics consisting of oral ciprofloxacin, The Kruskal-Wallis test was used for overall differences in engraftment and CD34 dose. If a significant difference PBPC priming and harvesting was found in the overall test, the Wilcoxon rank sum test All patients received G-CSF 5 g/kg subcutaneously for 7 was used for pairwise comparisons. consecutive days. PBPC were harvested on days 5-7. PBPCs were collected by the COBE (Denver, CO, USA) Spectra leukapheresis machine. Pheresis was continued Results until a minimum of 2 ϫ 10 6 /kg CD34 + cells were collected. PBPC were then processed as previously described. All patients completed the planned treatment and were evaluable for engraftment analysis. The median total number of CD34 + cells infused was 2.49, 2.33 and 3.01 ϫ 10 6 /kg Preparative chemotherapy regimens in the 1-day, 2-day and 3-day infusion groups, respectively. Patients were treated with one of three preparative chemoThere was no significant difference in median CD34 + PBPC therapy regimens. Patients with non-Hodgkin's lymphoma total dose in each group (P value = 0.53). Bone marrow and Hodgkin's disease received the Bu-Cy-Vp regimen engraftment data are shown in Table 3 . There was no sig-(busulfan: 1mg/kg by mouth every 6 h for 14 doses, days nificant difference in platelet or neutrophil engraftment Ϫ8 to Ϫ5; etoposide (VP-16): 50 mg/kg continuous times in the 2-or 3-day infusion groups. Granulocyte recovinfusion over 36 h on days Ϫ5 and Ϫ4; and cyclophosery occurred at a median of 11 days in the multiple infusion phamide 60 mg/kg i.v., daily for 2 days, days Ϫ3 and Ϫ2).
group, and 10 days in the single infusion group. The Patients with breast cancer received one of two preparative median days for platelets Ͼ20 ϫ 10 9 /l was 11 in the 1-day regimens: BuCy (busulfan 1 mg/kg by mouth every 6 h for infusion group and 12 days in the other two groups. 16 doses days Ϫ8-Ϫ5; cyclophosphamide 60 mg/kg i.v.,
The treatment protocol was well tolerated. PBPC were daily for 2 days, days Ϫ4 and Ϫ3) or STAMP V regimen infused with no unpredictable toxicities. shortly after the second day of infusion that responded to over 4 days, days Ϫ7-Ϫ4). The preparative chemotherapy regimen in each of the three treatment groups is shown in Table 2 . Table 3 Total CD34 + cell dose infused and engraftment data related to the infusion of cryopreserved cells may be related to the volumes of cryoprotectants infused. 7 While this study did not demonstrate a difference in toxicity with a multiday infusion schedule, we believe that spreading the intravenous fluid administration. One patient in the 3-day infusion of PBPCs over 1-2 days may be warranted to infusion group developed a brief episode of bradycardia, avoid administering a dose of DMSO greater than 1 g/kg which resolved spontaneously, during each PBPC infusion.
in 1 day. The toxicities in the three groups are shown in Table 4 .
Major transplant centers continuously attempt to minimize the cost of bone marrow transplantation.
8 Multiple-day PBPC infusion potentially adds to the cost of transDiscussion plantation by expanding the time and effort for stem cell processing, as well as increasing requirement for nursing PBPCs have been used in autologous transplantation for support during PBPC infusion. As our data demonstrate no more than a decade. While generally well tolerated, clinical benefit with multiple-day infusions of PBPC, we infusion of PBPCs may be associated with toxicities includbelieve that single-day infusion of PBPC should be ing skin rash, pruritus, flushing, fluid overload, wheezing, standard practice. hypotension, bradycardia and chest pain or tightness.
Abundant data exist describing engraftment characteristics of autologous PBPC transplants, yet little data exist References examining the toxicity of PBPC infusion. Peters et al the CSF-primed progenitor cells is on days Ϫ1, 0 and +1. detect significant differences in engraftment using an 781-786. infusion schedule of 1, 2 or 3 days. cells infused as a predictor of both neutrophil and platelet
